Nuclear Medicine revenue cycle control for authorized studies, documented doses, and complete claims.
Nuclear medicine revenue depends on exact handoffs across hospitals, imaging centers, and physician-based programs. Orders must support the selected PET, SPECT, or planar protocol. Authorization must match the study and indication. Administered radiopharmaceuticals, acquisition details, interpretations, coding, billing, denials, and A/R must remain connected through payment.
7 of top 20
U.S. health systems served
32M+
Coding charts processed annually
28M+
A/R claims managed annually
Imaging reimbursement breaks when the ordered study, administered agent, and submitted claim diverge.
Diagnostic imaging and radionuclide therapy combine procedure payment with high-cost agent economics. Payer rules vary by indication, protocol, site, and radiopharmaceutical. Specialists connect authorization, dose documentation, acquisition records, interpretation, coding, and claim validation. RevAmp and governance expose missing agent lines, unit conflicts, and component errors before they become denials or underpayments.
Match PET and SPECT approval to the performed protocol
Make administered-dose evidence support every agent line
Align professional and technical claims with actual ownership
Revenue cycle support organized around each study, dose, and interpretation.
Nuclear medicine requires controls that follow each study from order through payment. PET/CT needs indication-specific authorization and protocol alignment. Myocardial perfusion imaging depends on documented acquisition and interpretation. Radiopharmaceutical units must reflect the administered service. Technical and professional component claims must follow actual ownership. Support follows these dependencies across front-office, mid-office, and back-office work.
Front-office
Orders, indications, and modality approvals - fewer authorization and medical-necessity denials.
Mid-office
Dose records, acquisition protocols, and interpretations - defensible procedure and agent claims.
Back-office
NCCI edits and radiopharmaceutical variance - faster resolution with study-level evidence.
Matched study approvals. Complete dose evidence. Accurate procedure and agent payment.
Align indication, modality, and protocol with payer approval
Prior authorization review compares the order, diagnosis support, approved modality, and service date. Exceptions reach imaging owners before administration, reducing preventable PET and SPECT denials.
Connect administered agents with completed imaging services
Charge review reconciles dose documentation, acquisition records, procedure codes, and radiopharmaceutical lines. Missing agents and unit conflicts receive correction, protecting reimbursement for documented studies.
Release interpretations with correct component ownership
Workflow validation links completed reports with technical and professional billing responsibilities. Ownership and modifier exceptions resolve before claims advance, preventing component-related reductions.
Recover radiopharmaceutical variance by study and payer
Payment review separates packaged agents, separately payable items, and incorrect payer reductions. Study-level evidence routes valid variance to recovery, exposing recurring agent payment defects.
Imaging specialists, study-level intelligence, and governance for radiopharmaceutical reimbursement.
Expertise-led
Specialists who understand PET, SPECT, dose, and component-billing dependencies.
- Coders experienced in diagnostic imaging and therapeutic radionuclide workflows
- Authorization specialists who connect indications with modality and protocol requirements
- Revenue integrity analysts who reconcile administered agents and procedure charges
Technology-powered
RevAmp converts study, dose, report, claim, and payment signals into action.
- Exception queues for approval mismatches, missing doses, and incomplete reports
- Rules supporting NCCI, unit, component, and agent-line validation
- Dashboards linking study defects to denials, lag, variance, and aging
Operationally-governed
Study governance assigns ownership across imaging and revenue handoffs.
- Reviews track authorization match, protocol accuracy, dose evidence, and report lag
- Calibration connects payer changes with schedulers, technologists, physicians, and coders
- Corrective actions close repeat medical-necessity and radiopharmaceutical defects
Our Vision
Open accountability: Taking responsibility without taking control.
Nuclear medicine leaders retain control of clinical protocols, imaging systems, and payer strategy. We own agreed workflows and measures. Open Accountability connects authorization, order-to-protocol accuracy, dose documentation, interpretation completion, component billing, and agent payment variance. Transparent study queues identify where revenue risk entered and which owner must resolve it.
Authorization-to-study match
Approved modality, indication, and date align with performed imaging
Order-to-protocol accuracy
Acquisition follows the clinically ordered and payer-approved study
Dose documentation completeness
Administered agent and quantity support charge and claim lines
Procedure-to-agent claim match
Imaging and radiopharmaceutical lines travel together correctly
Agent payment-variance recovery
Incorrect radiopharmaceutical reductions reach evidence-based resolution
Why Us
What changes when every study carries complete clinical and dose evidence into billing.
A mismatched protocol, missing agent line, or incorrect unit creates preventable rework. First-Pass Performance checks study evidence before claims advance. Orders, authorizations, administered doses, acquisition records, interpretations, codes, and edits remain connected. Recurring failures return to the responsible workflow with evidence, ownership, and corrective action.
Rework-Powered Cleanup Machine
Our First-Pass Performance
Authorization and protocol mismatch
Modality or protocol differences surface after claim denial.
Order, indication, approval, and performed study receive prebilling validation.
Missing radiopharmaceutical line
Imaging bills while the documented administered agent remains uncharged.
Dose evidence and procedure charges reconcile before claim submission.
Unsupported dose or unit quantity
Charge units diverge from administration documentation and payer definitions.
Documented agent quantities drive calibrated unit and claim validation.
Incorrect component ownership
Professional and technical lines proceed without confirming service responsibility.
Equipment, acquisition, supervision, and interpretation ownership guide billing.
Hidden agent payment variance
Packaged and separately payable amounts age inside combined balances.
Study-level payment review routes incorrect reductions to recovery queues.
Revenue cycle thinking for leaders who need fewer surprises.
Explore Vee Healthtek perspectives on the forces reshaping revenue cycle performance, healthcare operations, technology adoption, and financial resilience.
Trace where a PET, SPECT, or therapy claim starts losing value.
Schedule a 30-minute working session with our nuclear medicine revenue cycle lead. Bring one pressure point: study authorization, protocol mismatch, dose documentation, component billing, radiopharmaceutical denials, or agent underpayments. We will trace the study from order through payment. Then we will identify first-pass controls that prevent repeat leakage.
Continue exploring expert perspectives, industry trends, and practical strategies for improving revenue cycle performance.
Explore Points Of ViewFrequently Asked Questions
How do you prevent PET or SPECT authorizations from mismatching the performed study?
What documentation supports radiopharmaceutical billing and units?
How should procedure and radiopharmaceutical lines appear on the claim?
How are professional and technical components managed for nuclear medicine?
How do you address medical-necessity denials for nuclear imaging?
Which KPIs expose radiopharmaceutical revenue leakage earliest?
Can support begin with one modality, agent, or denial category?